New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - tramadol hydrochloride 150mg - modified release tablet - 150 mg - active: tramadol hydrochloride 150mg excipient: colloidal silicon dioxide hypromellose   iron oxide red lactose monohydrate macrogol 6000 magnesium stearate microcrystalline cellulose propylene glycol purified talc quinoline yellow titanium dioxide - relief of moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - tramadol hydrochloride 200mg - modified release tablet - 200 mg - active: tramadol hydrochloride 200mg excipient: colloidal silicon dioxide ferrous oxide hypromellose   iron oxide red lactose monohydrate macrogol 6000 magnesium stearate microcrystalline cellulose propylene glycol purified talc quinoline yellow titanium dioxide - relief of moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - tramadol hydrochloride 50mg - modified release tablet - 50 mg - active: tramadol hydrochloride 50mg excipient: colloidal silicon dioxide hypromellose   iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate microcrystalline cellulose propylene glycol purified talc titanium dioxide - relief of moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rabies vaccine 2.5 [iu] - injection with diluent - 2.5 iu - active: rabies vaccine 2.5 [iu] excipient: disodium edetate potassium l-glutamate polygeline sodium chloride sucrose trometamol water for injection - active immunisation against rabies virus, including (a) pre-exposure immunisation, (b) post-exposure treatment following exposure to rabies virus

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - dermatophagoides farinae allergen extract 6 sq-hdm; dermatophagoides pteronyssinus allergen extract 6 sq-hdm - sublingual tablet - 12 sq-hdm - active: dermatophagoides farinae allergen extract 6 sq-hdm dermatophagoides pteronyssinus allergen extract 6 sq-hdm excipient: gelatin mannitol sodium hydroxide - acarizax is indicated for the treatment of adults diagnosed with: - house dust mite (hdm) allergic rhinitis (ar) not well controlled despite use of symptom relieving medication or - hdm allergic asthma (aa) not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis. patients' asthma status should be carefully evaluated before the initiation of treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - recombinant cholera toxin b subunit 1mg; vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated); vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated); vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) - oral suspension - active: recombinant cholera toxin b subunit 1mg vibrio cholerae inaba 48 classical biotype 31250 million organisms (heat inactivated) vibrio cholerae inaba 6973 el tor biotype 31250 million organisms (formalin inactivated) vibrio cholerae ogawa 50 classical biotype 62500 million organisms (equal parts heat inactivated and formalin inactivated) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate dihydrate citric acid raspberry flavour 52383 ap0551 saccharin sodium sodium bicarbonate sodium carbonate sodium citrate - active immunisation of adults and children from two years of age, who will be visiting areas with an ongoing or anticipated epidemic or who will be spending an extended period of time in areas in which cholera infection is a risk. the vaccine should be considered for foreign aid workers and others intending to visit or spend an extended period of time in areas endemic or epidemic for cholera.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - solifenacin succinate 10mg;   - film coated tablet - 10 mg - active: solifenacin succinate 10mg   excipient: hypromellose lactose monohydrate magnesium stearate maize starch opadry pink 03f14895 - vesicare is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - solifenacin succinate 5mg;   - film coated tablet - 5 mg - active: solifenacin succinate 5mg   excipient: hypromellose lactose monohydrate magnesium stearate maize starch opadry yellow 03f12967 - vesicare is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - mesalazine 500mg - suppository - 500 mg - active: mesalazine 500mg excipient: cetyl alcohol docusate sodium hard fat - treatment of ulcerative proctitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - bacillus calmette-guerin 0.75 mg/ml (when reconstituted with diluted sauton ajv (danish strain 1331) (vaccine)) - suspension for injection - 0.75 mg/ml - active: bacillus calmette-guerin 0.75 mg/ml (when reconstituted with diluted sauton ajv (danish strain 1331) (vaccine)) excipient: monosodium glutamate asparagine citric acid monohydrate dibasic potassium phosphate ferric ammonium citrate glycerol magnesium sulfate water for injection - active immunisation against tuberculosis